- Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European Urology. 2015 Academic Article GET IT
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Times cited: 3
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology. 2014 Information Resource GET IT
- Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
- Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012 Academic Article GET IT
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Times cited: 655